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Allogeneic stem cell transplantation is associated with a high risk of treatment-related 
mortality mainly caused by infections and graft-versus-host disease (GVHD). GVHD is 
characterized by severe immune dysregulation and impaired regeneration of different 
tissues, i.e., epithelial barriers and the liver. The balance between pro- and anti-inflammatory 
cytokine influences the risk of GVHD. Interleukin-6 (IL-6) is a cytokine that previously has been asso-
ciated with pro-inflammatory effects. However, more recent evidence from various autoimmune 
diseases (e.g., inflammatory bowel disease, rheumatoid arthritis) has shown that the IL-6 activity is 
more complex with important effects also on tissue homeostasis, regeneration, and metabolism. 
This review summarizes the current understanding of how pro-inflammatory IL-6 effects exerted 
during the peritransplant period shapes T-cell polarization with enhancement of Th17 differentia-
tion and suppression of regulatory T cells, and in addition we also review and discuss the results 
from trials exploring non-selective IL-6 inhibition in prophylaxis and treatment of GVHD. Emerging 
evidence suggests that the molecular strategy for targeting of IL-6-initiated intracellular signaling 
is important for the effect on GVHD. It will therefore be important to further characterize the role 
of IL-6 in the pathogenesis of GVHD to clarify whether combined IL-6 inhibition of both trans- 
(i.e., binding of the soluble IL-6/IL-6 receptor complex to cell surface gp130) and cis-signaling 
(i.e., IL-6 ligation of the IL-6 receptor/gp130 complex) or selective inhibition of trans-signaling 
should be tried in the prophylaxis and/or treatment of GVHD in allotransplant patients.
Keywords: interleukin-6, cytokine receptor gp130, allogeneic stem cell transplantation, graft-versus-host disease, 
Janus kinases
Abbreviations: ADAM, a disintegrin and metalloproteinase; AP-1, activator protein 1; ASCT, allogeneic stem cell transplanta-
tion; C/EBP-α, CCAAT/enhancer-binding protein alpha; CCL, chemokine (C–C motif) ligand 5; CNTF, ciliary neurotrophic 
factor; CRP, C-reactive proteins; CT-1, cardiotrophin-1; CT-2, cardiotrophin-2; DAMPs, damage-associated molecular patterns; 
APC, antigen-presenting cells; MHC, major histocompatibility complex; EGF, epidermal growth factor; ERK, extracellular 
signal-regulated kinases; FOXP3, forkhead box P3; GATA-3, globin transcription factor 3; GM-CSF, granulocyte–macrophage 
colony-stimulating factor; gp130, glycoprotein 130; GPL, gp130-like; GVHD, graft-versus-host disease; IBMTR, Center for 
International Blood & Marrow Transplant Research; ICAM-1, intercellular adhesion molecules; IFN-γ, interferon gamma; IL, 
interleukin; IL-6R, IL-6 receptor alpha; JAK, Janus kinase; LIF, leukemia inhibitory factor; LIFR, leukemia inhibitory factor 
receptor; MAPK, mitogen-activated protein kinase; MSCs, mesenchymal stem cells; NFAT, nuclear factor of activated T cells; 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NP, neuropoetin; OCM, oncostatin M; OSMR, oncos-
tatin M receptor; PAMPs, pathogen-associated molecular patterns; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma; 
RORγT, RAR-related orphan receptor gamma; sIL-6R, soluble IL-6R; SNP, single nucleotide polymorphism; SOCS, suppressor 
of cytokine signaling; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; Tfh, follicular B helper 
T cells; TGF, transforming growth factor; Th, T helper cells; TLR, toll-like receptor; TNFα, tumor necrosis factor alpha; Tregs, 
regulatory T cells; TYK, tyrosine kinase; VCAM-1, vascular cell adhesion protein 1; YAP1, yes-associated protein 1.
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iNTRODUCTiON
Allogeneic stem cell transplantation (ASCT) is a potentially 
curative therapeutic modality used primarily in the treatment of 
hematological malignancies and bone marrow failure syndromes 
(1, 2). Despite better supportive care and increased understand-
ing of the underlying pathophysiology processes, the majority of 
patients will experience either acute or chronic graft-versus-host 
disease (GVHD) (3).
Graft-versus-host disease is a complex biological process, 
which includes severe immune dysregulation with sustained 
inflammation (4). Several studies have identified interleukin-6 
(IL-6) and as an important factor in the pathophysiology of 
GVHD (5, 6). IL-6 is an important cytokine involved in both 
acute and chronic inflammation, and it plays a major role in 
several autoimmune disorders (7–9). It also mediates strong 
anti-inflammatory effects important for immunoregulation, 
metabolic control, and tissue regeneration (10). During the last 
15 years the pleiotropic effects of IL-6 in different organ systems 
have been reveled, and anti-IL-6 treatment has been approved 
for autoimmune and neoplastic disorders (11). With increasing 
insight into the complex signaling events induced by IL-6, more 
specific blockade of the anti-inflammatory functions of IL-6 is 
under development.
ASCT AND GvHD
In current ASCT protocols an initial conditioning treatment with 
chemotherapy and/or total body irradiation is followed by infusion 
of a stem cell graft derived from either umbilical cord blood, bone 
marrow, or peripheral blood of a healthy donor. Severe GVHD 
occurs in 20–30% of adult allotransplant recipients and is an 
important cause of transplant-related mortality (12, 13). GVHD 
is classified as either acute or chronic GVHD based on clinical 
characteristics. According to the clinical definitions, classic acute 
GVHD (aGVHD) develops within 100 days posttransplant with 
distinctive clinical features in the skin, gastrointestinal (GI) tract, 
or liver. However, manifestations of aGVHD can reoccur, persist, 
or present after day 100 posttransplant and is then classified as 
recurrent, persistent, or late onset aGVHD. Classical chronic 
GVHD is not limited to specific organ system and can present at 
any time after transplantation. The diagnosis of chronic GVHD 
is based on consensus criteria for each organ system involved. 
While  some clinical features are diagnostic (e.g., bronchiolitis 
obliterans and sclerotic features of the skin), other manifesta-
tions require additional clinical and/or histological criteria to be 
fulfilled. Some patients may also present as an overlap syndrome 
with clinical features of both acute and chronic GVHD.
Scoring systems have been developed to grade the severity 
of aGVHD based on the involvement of skin, GI-tract, and 
liver; the Glucksberg scale (grading aGVHD from I to IV) or 
the International Bone Marrow Transplant Registry (grading 
from A to D) are most widely used (14). First-line treatment for 
grade II–IV aGVHD is high-dose steroids (15), and a complete 
response is observed in 20–40% of patients (16, 17). There is no 
consensus regarding the preferred therapy for steroid-refractory 
aGVHD; commonly utilized options include TNFα blockade, 
anti-IL-6 antibodies, mTOR inhibitors, mycophenolate mofetil, 
and extracorporeal photopheresis (18). Despite several therapeu-
tic alternatives, patients with grade IV steroid-refractory aGVHD 
have a dismal long-term prognosis (15).
Donor T cells play major roles in the development of aGVHD, 
but multiple factors contribute to the overall risk of severe 
aGVHD. The development of aGVHD is believed to be a three-
step process each involving different subsets of immune cells 
(Figure 1) (19, 20). The first step is characterized by activation 
of the innate immune system; this results in a state of systemic 
inflammation prior to the introduction of donor T  cells. The 
chemotherapy and/or radiation used in the conditioning 
therapy invoke tissue damage with release of pro-inflammatory 
cytokines, e.g., IL-6, TNFα, IFN-γ, and IL-1. Damage to the GI 
barrier allows increased translocation of microorganisms from 
the gut microbiome, with subsequent increased levels of circulat-
ing lipopolysaccharide as well as molecules with pathogen- and 
damage-associated molecular patterns (PAMPs/DAMPs) (21). 
As a consequence, antigen-presenting cells (APC) secrete pro-
inflammatory cytokines and present host as well as pathogen 
peptides on their major histocompatibility complex molecules. 
A reduction of pretransplant inflammation (e.g., through the use 
of reduced intensity conditioning, reduction of gut microbiome 
levels) and the presence of genetic factors associated with reduced 
inflammatory responses are associated with a reduced risk of 
GVHD and treatment-related mortality (22–24). Several other 
factors also influence the pretransplant pro-inflammatory state, 
e.g., pro-inflammatory metabolites, soluble adhesion molecules, 
and factors associated with altered endothelial cell functions with 
increased vascular permeability (6, 25–27).
The second step is characterized by alloreactive T-cell acti-
vation, proliferation, and differentiation as a response to the 
presentation of host antigens by host APC in a proinflammatory 
context. Stimulation of specific T helper cell subsets is thought to 
be important for the initiation of later cytotoxic T-cell-mediated 
tissue damage (19, 20). Th1  cells release interferon-γ (IFN-γ) 
at high levels and express the transcription factors STAT4 and 
STAT1/T-bet (28, 29). This Th1 polarization seems to be impor-
tant for the development of aGVHD, especially in the GI tract 
(30). Additionally, Th2 cells characterized by expression of the 
transcription factor GATA-3 and secretion of anti-inflammatory 
cytokines IL-4, IL-10, and IL-13 (31) may also play a role in 
GVHD pathogenesis. The available studies of Th2 cells in GVHD 
have given conflicting results, but some studies have described 
an association between Th2 differentiation and pulmonary as 
well as skin involvement in aGVHD (30, 32, 33). Th17 cells are 
characterized by the expression of the transcription factor RORγt 
and IL-17 secretion (34), and IL-17-secreting T cells are thought 
to be important for aGVHD severity (35) as well as for early 
transplant-related severe lung injury (36). Finally, T  regulatory 
cells are a specialized Th subset characterized by expression of 
the transcription factor FOXP3 and high IL-2 receptor (CD25) 
expression. These cells play an important regulatory role by 
actively suppressing immune responses through their release of 
the anti-inflammatory cytokines IL-10, TGF-β, and IL-35 (37), 
and through direct interaction with other T cell subsets. Tregs are 
suppressed during GVHD, and resolution of GVHD is associated 
FiGURe 1 | A brief overview of acute GVHD pathogenesis. GVHD, graft-versus-host disease; DAMPS, danger-associated molecular patterns; PAMPS,  
pathogen-associated molecular patterns; APC, antigen-presenting cell; MΦ: macrophage.
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with restoration of the Treg function (38). Of particular interest, 
given the current topic of discussion, a majority of early post-
transplant circulating TCRαβ+ CD4+ and CD8+ T  cells release 
IL-6 at relatively high levels together with classical proinflamma-
tory cytokines such as IFN-γ and TNFα (39).
The third step of GVHD development is characterized by local 
action of cytotoxic CD8+ T  cells triggered by the local release 
of chemokines during the two first steps; these cells mediate 
direct cytotoxic effects upon target cell recognition, including 
secretion of perforin/granzyme and FAS-ligand. Other T-cell 
subsets contribute to the organ-specific manifestations of GVHD 
through polarization of macrophages toward a pro-inflammatory 
(M1) phenotype that further increase tissue damage through the 
release of oxidants and pro-inflammatory cytokines including 
TNF-α and IL-6 (40, 41).
iL-6 AND iTS ReCePTORS—CLASSiCAL 
SiGNALiNG AND TRANS-SiGNALiNG
The Structure and Release of iL-6
Interleukin-6 is a glycosylated protein with a molecular weight 
of 21–28 kDa (42). The systemic (serum/plasma) levels usually 
range from 1.8 to 14  pg/ml in healthy individuals with no 
significant age-dependent differences (43, 44). During inflam-
mation a more than 105-fold increase can be observed, often 
correlating with disease severity (45). IL-6 is released predomi-
nantly by cells of mesenchymal origin, fibroblasts, muscle cells, 
keratinocytes, monocytes, and macrophages (46) but can also 
be released by endothelial cells. During acute inflammation the 
main transcription factors responsible for the increased IL-6 
expression are NF-κB, CEBP-α, and AP-1 (47–49); these are 
activated by TNFα, IL-1β, the toll-receptor pathway, prosta-
glandins, and adipokines (50). IL-6 expression is also regulated 
by several miRNAs and RNases. Macrophages and monocytes 
appear to be the main sources of IL-6 during acute inflam-
mation, while T  cells seem to be a major contributor during 
chronic inflammation (51). However, IL-6 is also released in 
several physiological settings, e.g., during exercise when IL-6 
released by muscle tissue can cause a 100-fold increase in sys-
temic levels (52).
The iL-6 Receptor—Classical versus 
Trans-Signaling and iL-6 Cluster Signaling
The IL-6 receptor exists both in a membrane-bound and a soluble 
form; it has only a short intracellular domain and relies on the 
FiGURe 2 | An overview of the classical and trans-signaling.
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ubiquitously expressed gp130 cell membrane protein for intra-
cellular signal transduction (10). The membrane-bound receptor 
is only expressed by a limited number of cell types, including 
hepatocytes, neutrophils, naïve T cells, macrophages, and a subset 
of intestinal epithelial cells. Thus, in these cells, IL-6R signaling 
can be initiated through the membrane-associated complex of 
IL-6, IL-6R, and gp130. This is termed classical signaling and is 
often associated with tissue regeneration and anti-inflammatory 
properties (10).
Most soluble cytokine receptors inactivate cytokines by 
interfering with membrane receptor binding, whereas the soluble 
IL-6R receptor in complex with IL-6 binds and activates gp130 on 
cells that do not express the membrane-bound IL-6R (mIL-6R). 
Thus, cells that do not express the IL-6R themselves can be IL-6 
responsive; this mode of activation is called trans-signaling and 
seems important for many of the pro-inflammatory effects of IL-6 
(Figure 2) (42).
Soluble IL-6R is mainly formed through cleavage of mIL-
6R by a disintegrin and metalloprotease (ADAM) 10 and 17 
proteases. The soluble receptor is constitutively released by the 
liver and by hematopoietic cells, but activation of ADAM17 
during inflammation causes a rapid local increase in sIL-6R 
levels.
Dimeric gp130 is produced by alternative splicing and is 
secreted into serum in a soluble form; this dimer cannot bind 
IL-6 alone but only IL-6 in complex with sIL-6R. Classical IL-6 
signaling will then remain intact because of the free IL-6 and 
unaffected membrane-bound IL-6R, whereas IL-6 trans-signaling 
is quenched due to the binding of the soluble IL-6/IL-6R dimeric 
complex. Under normal circumstances the sgp130 has a higher 
molar concentration than the sIL-6R (two times higher), and 
gp130 thereby acts as a physiological buffer against IL-6 trans-
activation. Thus, IL-6 trans-signaling is regulated both by the 
release of the sIL-6R and the level of soluble gp130.
A third mode of IL-6 signaling termed IL-6 cluster signaling 
has recently been described (53). IL-6 is then loaded onto the 
IL-6 receptor as an intracellular process and thereafter expressed 
on the cell surface membrane of APC where the complex directly 
stimulates gp130 on T cells by direct cell–cell contact (53). So far, 
cluster signaling has only been described for the development of 
pathogenic Th17 cells in mice.
The iL-6 Cytokine Family
The IL-6 family includes IL-11, IL-27, IL-31, leukemia inhibi-
tory factor (LIF), OCM, ciliary neurotrophic factor (CNTF), 
CT-1, NP, CLC, CT-2, and humanin (Table 1). These proteins 
TABLe 1 | The IL-6 cytokine family—an overview of the receptor ligands/


















IL-31 OSMR or gp130-like (Gpl) OSMR + IL-31R (Gpl)
OSM OSMR + gp130
IL-6, interleukin-6; LIF, leukemia inhibitory factor; LIFR, LIF receptor; OSMR, OSM-
receptor; CNTF, ciliary neurotrophic factor; CNTFR, CNTF receptor; sCNTFR, soluble 
CNTF receptor; CT-1R, CT-1 receptor; WSX-1 alias:IL-27RA.
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share structural resemblance with IL-6 and utilize gp130 or a 
gp130-like molecule for intracellular signal transduction (54). 
However, more ligand-specific receptor subunits are also used, 
including leukemia inhibitory factor receptor, OSMR, and 
IL-27RA. Some of these ligand-specific receptors have intracel-
lular domains that can stimulate other signaling cascades than 
that of gp130. There is also cross-reactivity between the different 
IL-6 family cytokines and their receptors. Based on the differ-
ent combinations of the utilized transmembrane proteins, the 
IL-6 cytokine family can be divided into different subgroups 
(Table 1) (55).
Receptor-initiated intracellular Signal 
Transduction
Gp130 is non-covalently associated with the Janus kinases (JAKs) 
JAK1, JAK2, and TYK2. Following receptor ligation, the JAKs are 
auto-phosphorylated, and they also phosphorylate gp130. This 
phosphorylation provides docking sites for phosphorylation of 
STAT1, STAT3, and the tyrosine phosphatase SHP-2. After phos-
phorylation, STAT3 dimerizes and is translocated to the nucleus 
where it acts as a transcription factor (56). Furthermore, SHP-2 
activates the RAS/RAF/MAPK/ERK pathway, whereas gp130 
activation also leads to activation of the PI3k–AKT pathway 
together with the transcriptional regulator YAP1 (Figure 2). Most 
of the IL-6 effects seem to be STAT3-mediated. STAT3 is con-
trolled by a negative feedback mechanism; it induces expression 
of SOCS proteins and activation of the SHP-2 phosphatase. SOCS3 
then binds with high affinity to the same phosphorylated binding 
site on gp130 as JAK1/2 and thereby inhibits further intracellular 
signaling. Even though SOCS1 can also bind to the same site, this 
interaction is believed to be functionally less important in vivo. 
IL-6 signaling is also inhibited by internalization and degradation 
of the receptor complex, and internalization of gp130 prevents 
further signaling of the IL-6 cytokines.
experimental Tools for examining 
Classical iL-6 Signaling and  
Trans-Signaling
The development of the two designer proteins sgp130FC and 
Hyper-IL-6 has made it possible to investigate the in vitro and 
in  vivo effects of IL-6 classical and trans-signaling (42). The 
sgp130FC is constituted of two monomeric sgp130 molecules 
coupled with a human FC region. The affinity of sgp130FC to the 
IL-6/sIL-6 complex is 100- to 1,000-folds higher than naturally 
occurring sgp130 monomers, and it can abolish IL-6 trans-sign-
aling without affecting the classical IL-6 signaling. The designer 
cytokines Hyper-IL-6 consists of IL-6 that is directly linked with 
the IL-6 receptor. Hyper IL-6 binds and activates gp130 on cells 
not expressing mIL-6 receptor. The use of these molecules in 
several mouse models has given valuable insight into IL-6 biol-
ogy, e.g., antigen-induced arthritis, inflammatory bowel disease, 
colitis associated cancer, pancreatitis induced acute lung injury, 
and hepatocellular carcinoma model (57–61).
iL-6, THe ACUTe PHASe ReSPONSe  
AND THe RiSK OF GvHD
The acute phase response represents a physiological increase in 
the levels of certain serum proteins due to increased production 
and release especially by the liver, and this includes C-reactive 
protein (CRP), serum amyloid P, ferritin, mannose binding 
protein, and fibrinogen (62). IL-6 is the main driver of the 
response, but other cytokines (IL-1, IL-8/CXCL8, and TNFα) also 
contribute (62). The levels of several acute phase proteins (e.g., 
CRP) is strongly correlated with IL-6 levels, and the IL-6 levels are 
again often correlated with the extent of tissue damage. In some 
malignancies there is evidence of chronic inflammation with a 
persisting acute phase response; but this response may also be due 
to constitutive IL-6 release by malignant cells (63, 64).
Both IL-6 and CRP levels are elevated in most patients prior to 
ASCT, and this may be due to chronic fungal or bacterial infections, 
GI barrier break, or residual malignant disease (65, 66). The impact 
of pretransplant CRP levels after allotransplantation has been 
investigated in several studies (6, 65–71). Elevated CRP levels seem 
then to independently entail a higher transplant-related morality 
without increasing the risk of acute or chronic GVHD. The effect of 
both CRP and IL-6 levels has only been investigated in two studies 
(6, 66). Although CRP and IL-6 serum levels are highly corre-
lated, CRP seems to independently influence the TRM, while the 
pretransplant IL-6 level does not seem to have a similar impact 
on TRM or GVHD. A possible explanation for this could be that 
the CRP levels are influenced by several comorbidities and not 
only IL-6.
iL-6, eFFeCTS ON iMMUNOCOMPeTeNT 
CeLLS
Interleukin-6 has both direct and indirect effects on immuno-
competent cells involved in the development of GVHD. Several 
of these effects are summarized in Table 2. First, IL-6 is essential 
TABLe 2 | Important effects of interleukin-6 (IL-6) on immunocompetent cells 
involved graft-versus-host disease (GVHD) and on GVHD target organs.
iL-6 effects on immunocompetent cells
T cells: Membrane-bound IL-6R mainly expressed on naïve and memory  
T cells (60, 72).
Naïve T cells: IL-6 causes STAT3 activation, resulting in SOCS1 expression  
and thereby inhibited Th1 polarization (73).
Th1 cells: Suppressed Th1 development (73).
Th2 cells: Enhanced Th2/polarization/development through STAT3 
dependent c-maf expression and STAT3 independent NFAT expression (73).
Th17 cells: Enhanced Th17 development through IL-6- and IL-21-induced 
STAT3 activation followed by increased RORγT expression (56, 73–76). 
Differentiation from naïve T cells to Th17 relies largely on classical IL-6 
signaling, whereas maintenance of Th17 cells depends on trans-signaling 
(60). STAT3 activation in naïve T cells by mIL-6R/IL-6 complex on the dendritic 
cells (cluster signaling) has been shown to be important for the development 
of pathogenic Th17 cells (53).
Th22 cells: The development depends on combined effects of IL-6, TNFα, 
IL-1β, and the aryl hydrocarbon receptor (77).
Tregs: Suppressed Treg development, inhibition of FOXP3 expression. 
Indirect effects of IL-6 may increase Treg development through increased 
release of anti-inflammatory cytokines (78).
Tfh: IL-6 seems to commit T cells to Thf differentiation (79, 80).
Dendritic cells and monocytes
Dendritic cells: Inhibits differentiation of dendritic cell from bone marrow 
progenitors, and decreased responsiveness of dendritic cells. STAT3 
activation seems important for these effects (81, 82).
Monocytes: Increased M-CSF expression favors differentiation into 
macrophages rather than dendritic cells (83).
B cells: A key factor for regulation of B cell survival and maturation through 
both direct as well as indirect effects by stimulation of Tfh development (79, 80). 
Supports development into long-lived plasma cells (84).
Mesenchymal stem cells (MSCs): MSCs have unique immunomodulatory 
effects and have therefore been used in the treatment of acute and chronic 
GVHD. MSCs suppress Th1 and Th17 cells and induce Treg expansion through 
the release of multiple cytokines, including IL-6 and the IL-6 family cytokine 
LIF (85). Pro-inflammatory signals upregulate the constitutive IL-6 release by 
MSCs (86), and autocrine IL-6 stimulation will thereafter induce the release of 
immunosuppressive prostaglandin E2 by the MSCs (87). Furthermore,  
LIF secretion by MSCs inhibits T-cell proliferation in mixed lymphocyte reaction 
and seems to enhance the generation of Tregs (88). Autocrine IL-6 stimulation 
seems important for their survival, maintenance of stemness, and regulation 
of proliferation; ERK1/2 seems important for these effects (89, 90). MSC/T cell 
cross talk seems to increase local IL-6 levels (91).
effects of iL-6 on leukocyte migration during local inflammation
• Enhances recruitment of primed T cells to inflamed tissue and entry of naïve 
T cells to lymphoid organs (54).
• Fever alone increases leukocyte extravasation through gp130 dependent 
mechanisms (92).
• IL-6 trans-signaling as well as signaling initiated by other IL-6 family members 
increase l-selectin expression by T cells through ERK1/2 activation and 
increase their extravasation (93, 94).
• IL-6 trans-signaling increases vascular expression of both adhesion the 
molecules (e.g., ICAM-1, VCAM-1, CD62E, and release of chemoattractant 
(CCL2, CXCL10, CCL4, CCL5, CCL11, and CCL17) (95).
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cells. Second, IL-6-signaling is crucial for trafficking of immune 
cells to inflamed tissues and lymphoid organs. This is caused both 
by altered expression of adhesion molecules by endothelial cells 
and by expression of their ligands by immunocompetent cells. 
Third, IL-6 has important functions in GVHD target organs, and 
there may therefore be a risk of combined injury during GVHD 
(e.g., GVHD-induced immune-mediated damage, pharmaco-
logical toxicity, and IL-6 inhibition). Finally, IL-6 together with 
TNF-α released from macrophages has been reported to directly/
independently contribute to tissue damage in GVHD (40).
iL-6 A ReGULATOR OF STeM CeLLS  
AND TiSSUe ReGeNeRATiON
Interleukin-6 is important for the regulation of stem cells and 
tissue regeneration in several organs. This has been best dem-
onstrated for hematopoiesis, liver cells, GI mucosa, and muscle 
cells. A complete overview of these effects is beyond the scope 
of this article. A brief overview of the major effects of IL-6 in 
these different organ systems is given in Table 3. Impaired IL-6 
function in these organs is associated with reduced regeneration 
after injury, and IL-6 dysregulation during chronic inflammation 
can contribute to organ dysfunction.
THe ROLe OF iL-6 iN GvHD—LeSSONS 
FROM ANiMAL MODeLS
The role of IL-6 in acute and chronic GVHD has been investigated 
in several mouse models. Givon et al. (110) examined the effect 
of IL-6 on bone marrow reconstitution after syngeneic, semi- 
allogenic, and ASCT and found that posttransplant treatment 
with subcutaneous recombinant IL-6 significantly supported 
white blood count reconstitution and improved survival in syn-
geneic as well as allogenic transplantation. This effect was only 
significant for animals transplanted with a low stem cell dose. 
In contrast, mice receiving IL-6 showed increases in both the 
severity of and mortality from GVHD.
Chen et al. (111) observed increased systemic IL-6 and IL-6R 
levels early after both syngeneic and allogeneic transplantation. 
These levels returned to baseline over time in the syngeneic group, 
whereas IL-6 levels remained high in mice developing GVHD. 
Both IL-6 and IL-6R expression increased in the liver and colon 
(but were stable in the spleen), and the highest IL-6R mRNA 
levels were observed in these two organs. Selective IL-6 knockout 
in neither recipient nor donor cells was sufficient to protect from 
GVHD. However, GVHD treatment with anti-IL-6 resulted in 
significantly lower weight loss, less histopathological evidence of 
damage to colon, liver, and lungs, and significantly increased Treg 
levels in the spleen. The increased Treg levels were not dependent 
on an intact thymus; rather the IL-6 blockade increased periph-
eral generation of Treg cells and reduced the levels of Th1 and 
Th17 cells. Similar results were shown by Noguchi et al. (112); 
treatment with an anti-IL-6 antibody reduced liver enzyme levels 
as well as the occurrence of organ failure and was associated with 
reduced infiltration of Th1 and Th17 cells, increased Treg cells, 
and improved survival.
for maturation, proliferation, differentiation, and maintenance of 
B cells/plasma cells and several proinflammatory T-cell subsets. 
IL-6 seems to enhance the development of pro-inflammatory 
Th17 and Th2 cell and to inhibit the development T regulatory 
TABLe 3 | Important effects of interleukin-6 (IL-6) in target organs of  
graft-versus-host disease (GVHD) and on metabolism.
iL-6 and the target organs of GvHD
Liver: IL-6 together with other cytokines is important for liver regeneration; 
the prolonged effect of trans-stimulation seems more important than classical 
signaling (96, 97). Clinical IL-6 inhibition can cause increased liver transaminases 
(98), but it is not known whether IL-6 targeting, potentially liver-toxic drugs and 
concomitant immune-mediated injury due to GVHD, will increase the risk of 
severe liver toxicity in allotransplant recipients.
Gastrointestinal mucosa: IL-6/STAT3 is important for regeneration of 
intestinal epithelium, maintain barrier integrity, ensure adequate secretion 
of antimicrobial peptide, support proliferation, and facilitate migration of 
intraepithelial lymphocytes (99–101). Inhibition of IL-6 signaling (especially 
trans-activation) suppresses colitis (59, 102). Clinical use of IL-6 inhibition is 
associated with increased risk of bowel perforation (103).
iL-6 and the effects on metabolism
Cachexia: High IL-6 levels are often observed in patients with cachexia. 
Although some studies have shown that IL-6 blockade can attenuate anemia 
and muscle loss in cancer patients, the role of IL-6 in the metabolic changes 
during cachexia is still unclear.
Glucose tolerance: Obesity/glucose intolerance is associated with low-grade 
chronic inflammation and high baseline IL-6 levels (104). Insulin treatment 
reduces IL-6 levels (105, 106). IL-6 secreted by adipocytes seems to favor the 
development of anti-inflammatory M2 (107). Inhibition of the mIL-6R in the liver is 
associated with reduced glucose tolerance and dyslipidemia (108).
Muscle cells: IL-6 is important in regeneration of muscle after injury through 
a direct effect on muscle stem cell-IL-6 (109). IL-6 is also actively secreted by 
muscle cells and has important endocrine and metabolic effects.
TABLe 4 | The role of STAT3 in regulation of activation and differentiation of 
immune cells in allogeneic stem cell transplantation; important observations in 
animal studies and experimental in vitro studies.
Pretransplant intervention: Pretransplant inhibition of STAT3 in graft T cells 
through upstream pharmacological JAK2 inhibition reduced graft-versus-host 
disease (GVHD) mortality and increased the levels of Tregs (116).
GvHD mortality: STAT3 ablation reduces posttransplant mortality as well as the 
severity of both acute and chronic GVHD, especially GVHD severity in the skin 
and colon (119, 120).
Tolerance induction: JAK2 inhibition seems to be more effective than interleukin-6 
(IL-6) neutralization for induction of immunological tolerance (117, 118).
T cell proliferation: Proliferating alloreactive T cells expressed higher levels 
of phosphorylated STAT3 compared to proliferating T cells in syngeneic 
transplantations (116).
Dendritic cells: Pharmacological inhibition of STAT3 phosphorylation by IL-6 
neutralizing antibodies or JAK2 inhibitors does not inhibit dendritic cells (117).
Regulatory T cells: Equal numbers of Treg cells are observed in both STAT3-wt 
and knockout mice after syngenic transplantation, while after allotransplantation 
mice STAT3 expression is associated with a lower number of Tregs cells (119).
The STAT3 effects differ between nTregs and iTregs; nTregs with impaired STAT3 
function do not prevent GVHD, whereas STAT3 knockdown in iTreg prevents 
GVHD (119).
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Tawara et al. (113) investigated the effect of IL-6 derived from 
donor T cells. In contrast to the findings by Chen et al., selective 
IL-6 knockout in donor/graft T  cells was associated with less 
severe GVHD and prolonged survival. Pretransplant anti-IL-6 
treatment also significantly improved survival and clinical as well 
as histopathological severity of GVHD, but the Treg levels were 
not altered. Importantly, the GVL effect was maintained despite 
the reduction in GVHD. The systemic cytokine levels and the 
levels of circulating cells were not altered by the treatment, and 
selective ablation of IL-6 in recipient bone marrow cells did not 
reduce the occurrence or severity of GVHD.
Organ-specific effects of IL-6 in GVHD have been investigated 
in two different mouse models. Varelias et al. (36) examined the 
role of IL-6 in idiopathic pulmonary syndrome (IPS) after ASCT 
and demonstrated that local secretion of IL-6 induced Th17 cell 
differentiation that was necessary for disease development. IPS 
development could be prevented by IL-17 knockout or by the 
use of neutralizing antibodies against IL-17. In a second study, 
Le Huu et al. (114) investigated the role of IL-6 in a sclerodermous 
cGVHD model and observed that IL-6 levels increased during 
disease progression. Treatment with IL-6-neutralizing antibodies 
prior to manifestations of scleroderma significantly decreased 
disease severity, while no reduction was observed when IL-6 
neutralization was started after the onset of cGVHD. Treatment 
with anti-IL-6 was associated with a significant increase in the 
number of splenic Treg cells, whereas the expression of IFN-γ, 
TNFα, IL-6, IL-18, TGF-β1, CCL2, CCL3, and CCL5 in affected 
skin was significantly reduced.
eXPeRiMeNTAL STUDieS SUGGeST  
A ROLe OF JAK2–STAT3 ACTivATiON  
iN ALLOReCOGNiTiON AND GvHD 
DeveLOPMeNT
The role of STAT3 in the regulation of activation and differen-
tiation of Tregs and Th17 cells after allotransplantation has been 
investigated in several mouse models (i.e., STAT3-knockout 
mice) and in vitro models. Emerging evidence also suggests that 
activation of STATs in B cells is also important for GVHD (115). 
A complete review of this scientific field is beyond the scope of 
this article, but an overview of important observations is given 
in Table  4 (116–120). In summary, these reports suggest that 
targeting of IL-6/JAK2/STAT3 signaling can be effective against 
the development of GVHD. Treatment can be given either by 
graft engineering or as posttransplant therapy, the function of 
several immunocompetent cells will then be affected, and reduced 
GVHD severity as well as improved survival has been observed. 
Based on these findings, treatment with the JAK1/2 inhibitor 
ruxolitinib has been tested in patients with manifest chronic 
and aGVHD, and it was reported to improve GVHD and reduce 
serum cytokine levels (121, 122). Patients included in these two 
studies are heterogeneous with respect to GVHD manifestations, 
previously GVHD prophylaxis and treatment. Further well-
designed studies are definitely needed to determine the efficacy 
and toxicity of JAK2/STAT3 blockade in allotransplant recipients.
iL-6 iN ASCT—CLiNiCAL DATA
aGvHD and iL-6 Polymorphism
Specific single nucleotide polymorphisms (SNPs) in the IL-6R 
and the IL-6 gene are associated with higher serum levels of IL-6 
and sIL-6R. Especially the SNP 174  G  <  C (rs1800795) in the 
TABLe 5 | Summary of studies investigating the influence of different SNPs in the IL-6 and IL-6R on outcome after allogenic stem cell transplantation.
Reference Year Patients Donor type Stem cell 
source
AGvHD cGvHD Survival
PB BM Genotype Risk
iL-6 rs1800795 or rs1800797
Alam et al. (133) 2015 268 MRD 184 184 NR D Increased NR No effect
Chien et al. (128) 2012 1,298 Related 612 377 921 D Increased NR NR
Unrelated 686
Ambruzova et al. (125) 2008 56 Sibling NR NR D Increased No Decreased
Ambruzova et al. (126) 2009 166 121 related 144 22 R No Borderline 
decreased45 unrelated
Karabon et al. (134) 2005 93 Sibling NR NR D/R Increased NR No
Laguila Visentainer et al. (131) 2005 118 Sibling 36 82 No effect Increased No effect
Mullighan et al. (137) 2004 160 154 sibling 100 60 D Increased No No effect
Lin et al. (132) 2003 993 Sibling No effect NR NR
Rocha et al. (136) 2002 107 Sibling 107 No effect No effect No effect
Socié et al. (135) 2001 100 Sibling No effect Increased risk NR
Cavet et al. (127) 2001 80 Sibling 80 R Tendency higher 
grade
R or D increased NR
iL-6R polymorphism, rs4845617
Kim et al. (129, 130) 2012, 2014 394 MRD 288 276 118 Increased risk chronic eye GVHD
MMD19 Recipient genotype associated with increased NRM
MUD84
BM, bone marrow; D, donor; MMD, mismatched related donor; MRD, matched related donor; MUD, matched unrelated donor; NR, not reported; NRM, non-relapse mortality; PB, 
peripheral blood stem cell collection; R, recipient; aGVHD, acute GVHD; SNPs, single nucleotide polymorphisms; GVHD, graft-versus-host disease.
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IL-6 promoter region affects the transcription and secretion of 
IL-6 and has been associated with several autoimmune disorders 
(123, 124). A summary of the 10 studies that have examined the 
role of this specific SNP in acute and chronic GVHD is presented 
in Table 5; of note, only one of those studies examined effects 
of SNPs both in the IL-6 and IL-6R gene (125–137). A meta-
analysis of seven studies published during the period 2001–2012 
was performed by Choi et al. (138); they concluded that patients 
who received grafts from donors either hetero- or homozygous 
for the IL-6 G allele had significantly increased risk of developing 
aGVHD grade I–IV (odds ratio 3.30) or grade II–IV (odds ratio 
1.73). To date, the largest study investigating the role of IL-6 poly-
morphisms in GVHD is that of Chien et al. (128), which included 
1,298 patients. They investigated IL-6 SNP polymorphisms 
together with 14 other candidate genes, and their unadjusted and 
adjusted analyses of patients with unrelated donors showed that 
the donor genotype rs1800795 was associated with a 20–50% 
increased risk of grade II–IV aGVHD.
Kim et al. (129, 130) investigated the effects of 259 different 
SNPs on outcome after ASCT. While they did not observe any 
effect of SNPs in the IL-6 gene, patients with an SNP in the IL-6R 
gene (rs4845617) showed decreased relapse-free survival. In 
a new study of the same patients, univariate analysis identified 
several SNPs in the IL-6R (rs2229238, rs4072391, rs4379670, 
and rs7514452) that were associated with an increased risk of 
aGVHD, but they could not predict aGVHD in a multivariate 
analysis. The SNP (rs4845617) was predictive of cGVHD of the 
eyes and could be included in a model to predict GVHD.
The IL-6 receptor Asp358Ala SNP (rs2228145) increases the 
proteolytic conversion rates by ADAM proteases, and this leads to 
higher soluble IL-6R levels; it is also associated with a lower baseline 
CRP and decreased incidence of autoimmune disorders (139). To 
the best of our knowledge, the effect of this specific SNP on the risk 
of complications after allotransplantation has not been investigated.
iL-6 Level and Clinical Outcome
Pretransplant IL-6 levels in allotransplant recipients show a wide 
variation and a strong correlation with pretransplant CRP levels 
but do not seem to predict survival, risk of GVHD, or non-relapse 
mortality after transplantation (6). This study included only patients 
with related donors (mainly matched sibling donors) transplanted 
in complete remission (all except 1 of the 99 patients), and the 
pretransplant systemic levels of all IL-6 family members were stud-
ied. Only pretransplant IL-31 influenced late transplant-related 
mortality. However, there was a significant association between 
pretransplant IL-6 and early postconditioning weight gain (i.e., 
fluid retention), and this fluid retention in turn was a risk factor 
for aGVHD, transplant-related mortality, and overall survival. The 
authors concluded that pretransplant CRP, pretransplant IL-31, and 
early posttransplant fluid retention were independent risk factors 
for transplant-related mortality and survival after allotransplanta-
tion. The strong association between pretransplant IL-6 levels and 
vascular permeability/fluid retention suggests that effects of IL-6 
on endothelial cells may contribute to a high-risk phenotype.
After onset of chemotherapy, IL-6 levels rise significantly and 
reach a maximum during the two first weeks before returning 
to baseline in most patients (140, 141). Increased systemic IL-6 
levels are also observed during febrile illnesses and toxic compli-
cations in patients with hematological malignancies. Both after 
intensive chemotherapy and allotransplantation, the levels are 
TABLe 6 | A comparison of the two IL-6 blocking monoclonal antibodies 
approved for clinical use.
Characteristics Tocilicumab Siltuximab
Specificity Anti IL-6R (membrane and soluble) Anti IL-6
Antibody structure Humanized Chimeric 
(mouse/human)
Administration Subcutaneous or intravenous Intravenous




Systemic juvenile idiopathic arthritis
Example of reported 
off-label use
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strongly associated with the CRP levels and are accompanied by a 
decrease in sIL-6R levels (142–144). Conflicting results have been 
reported about IL-6 levels in aGVHD; some have reported high 
levels prior to aGVHD (36, 145, 146), whereas others have not 
been able to verify this (147–149). Increased IL-6 levels have also 
been associated with severe pulmonary toxicity and with reduced 
survival after autologous stem cell transplantation (140, 150).
iL-6 Blockade in Prevention of GvHD
Only two drugs inhibiting IL-6 or the IL-6R are currently 
approved for clinical use; tocilizumab is used in rheumatoid 
arthritis and systemic sclerosis, whereas siltuximab is approved 
for treatment of multicentric Castleman’s disease (Table  6). 
Tocilizumab is a humanized monoclonal antibody that binds 
to both membrane-bound and soluble IL-6R, while siltuximab 
is a chimeric monoclonal antibody binding circulating IL-6 
(151). Tocilizumab is generally well tolerated in patients with 
rheumatoid arthritis; the most commonly reported side effects 
being dyslipidemia (21–25%), increased liver transaminases 
(5–6%), and transient decreases in neutrophil counts (152–154). 
IL-6 blockade inhibits the acute phase response and may thereby 
mask signs of acute severe infections. Although some studies 
in rheumatoid arthritis have shown a higher rate of infections 
in patients treated with tocilizumab (153, 154), this could not 
be confirmed in a large multicenter study (152). Several other 
IL-6 inhibitory small molecules and monoclonal antibodies are 
currently in clinical trials both for autoimmune disorders and 
different types of cancer (151).
IL-6 blockade as prophylaxis against GVHD has been 
investigated in only one study (155), where a single dose of tocili-
zumab 8 mg/kg (maximum dose 800 mg) was added to standard 
GVHD prophylaxis with cyclosporine A and methotrexate in 48 
patients that underwent T-cell replete allotransplantation with 
myeloablative or reduced intensity conditioning regimes. The 
incidence of grade III–IV aGVHD and the non-relapse mortal-
ity were only 4%. The incidence of severe aGVHD was also low 
in patients receiving myeloablative conditioning based on total 
body irradiation; a treatment protocol usually associated with a 
high risk of GVHD. The addition of tocilizumab appeared gener-
ally safe with no increase in graft rejections, time to neutrophil 
regeneration, chimerism at day  +  40 posttransplant, or early 
relapse compared to historical controls. Only three patients 
experienced severe liver toxicity during the first month after 
transplantation.
To our knowledge, there is only one ongoing trial that inves-
tigates the role of adding IL-6 blockade to standard prophylactic 
GVHD-therapy (NCT02206035). In this open label phase II 
trial, tocilizumab is given in addition to tacrolimus/ methotrexate 
and compared with a contemporary control cohort. The pri-
mary endpoint is grade II–IV GVHD during the first 180 days 
posttransplant. In a second trial, the rate of cytokines release 
syndrome with and without IL-6 blockade with tocilizumab will 
be investigated in a small number of patients receiving haploiden-
tical transplantation with posttransplantation cyclophosphamide 
(NCT02057770).
iL-6 Blockade in the Treatment of GvHD
In addition to a few case reports (156–158) and conference 
abstracts (159) only two published case series report the effects of 
tocilizumab in the treatment of acute steroid-refractory aGVHD 
(Table 7) (160, 161). Drobyski et al. (161) described the effects 
in eight patients (two acute and two chronic GVHD) where toci-
lizumab was administered once every 3–4 weeks. Five patients 
had grade IV GVHD (four gut and one skin involvement), while 
one patient had grade II gut, and the last patient had grade III 
liver affection. One of these patients died early after tocilizumab 
administration and was not evaluable, one patient did not 
respond, three patients were classified as partial responders, and 
two patients were considered complete responders. In one of the 
patients with partial response, the treatment was discontinued 
because one could not exclude the possibility that tocilizumab 
worsened preexisting hyperbilirubinemia. A transient increase 
in liver transaminases was also observed in several patients. The 
authors concluded that infections were responsible for the major 
adverse events associated with tocilizumab administration, with 
a total of 13 documented infections.
Roddy et  al. (160) reported the effect of tocilizumab in 
patients with steroid-refractory aGVHD; seven patients with 
grade IV and two with grade III aGVHD. Tocilizumab was 
administered in a similar manner as in the previously reported 
study. Five patients were classified as non-responders, two 
patients were classified as complete responder, and two patients 
had mixed response with persistence of severe aGVHD in one 
organ but resolved disease in other organs. In this study, four 
patients suffered from infectious episodes with two deaths being 
reported, but no liver toxicity was observed. Only one ongoing 
study for treatment of steroid-refractory aGVHD has been 
registered (https://clinicaltrials.gov, NCT01475162), but this 
study was ended because the risks of toxicity seemed to outweigh 
the potential benefits.
CONCLUDiNG ReMARKS
Graft-versus-host disease is a complex, multi-systemic disease 
in which local and systemic factors play a role in orchestrating 
inflammation, tissue repair, and regeneration. The impact of 
SNPs in the IL-6 gene on GVHD risk indicates that IL-6 plays 
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TABLe 7 | Summary of studies with IL-6 receptor (tocilizumab) or JAK2 (ruxolitinib) blockade in treatment of chronic and acute steroid-refractory GVHD.
Reference Patients (n) aGvHD (n) cGvHD (n) Organ involvement (patients) Response aGvHD Response cGvHD
Skin Gastrointestinal Liver
Tocilizumab
Drobyski et al. (161) 8 6 2 Grade II: 3 Grade II: 1 Grade III: 1 CR 2, PR 2, NR1, NR 11 Stabilization 1 PR
Grade IV: 1 Grade III: 4
Roddy et al. (160) 9 9 0 Grade II: 1 Grade I: 1 Grade I: 1 CR: 2, CR in single 
organ system 2
N/A
Grade II: 2 Grade II: 2
Grade III: 2 Grade III: 1
Grade IV: 4 Grade IV: 2
Ganetsky et al. (159) 5 5 All patients Glücksberg grade IV CR 5 N/A
Ruxolitinib
Zeiser et al. (122) 95 54 41 All patients with aGVHD grade III/IV, not otherwise 
specified
ORR 44, CR 25 35
Spoerl et al. (121) 6 4 2 Grade III: 2, Grade IV: 1 Grade IV: 2 Grade III: 1 CR 1, PR 3 2
CR, complete response; PR, partial response; NR, non-response; ORR, overall response rate; N/A, not applicable; GVHD, graft-versus-host disease; aGVHD, acute GVHD.
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a role during early GVHD development. Blockade of the pro-
inflammatory effects of IL-6 seems to be a possible therapeutic 
strategy since IL-6 and STAT3 activation are closely linked to 
the development of both Th17 and Treg cells, and since early 
STAT3 phosphorylation posttransplant seems to precede devel-
opment of GVHD (118). However, currently available clinical 
data indicate that IL-6 blockade is most effective when used 
as GVHD prophylaxis, whereas manifest GVHD might be less 
susceptible to IL-6 blockade. An unselective systemic blockade 
of IL-6 is probably not without caveats, given the physiological 
importance of IL-6 in tissue regeneration and homeostasis in 
both the liver and GI tract, two organs commonly affected both 
in acute and chronic GVHD.
Most of the pro-inflammatory effects of IL-6 seem to be caused 
by trans-signaling. A fusion protein consisting of the immuno-
globulin Fc region and gp130 can be used for specific blocking 
of trans-signaling (56); this protein binds IL-6 in complex with 
sIL-6R but cannot bind free IL-6. Treatment with this selective 
inhibitor inhibits inflammation and preserves the regenerative 
effects of IL-6 in mouse models of a wide variety of diseases, 
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associated lung injury (56). All experimental models of GVHD 
explored so far have utilized either genetic or pharmacological 
blocking of IL-6, and little is therefore known about the relative 
contributions of trans- versus cis-/classical IL-6 signaling in these 
settings. Further models should therefore address the use of selec-
tive blockade of IL-6 trans-signaling after ASCT.
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